News

We send the latest information from SMC Laboratories.

2024.07.05

PRODUCTS AND SERVICE PUBLICATION

MOA demonstration #3 【GLP-1】|Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice

Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1.   Speaking of GLP-…

READ MORE

2024.06.26

PRODUCTS AND SERVICE

Custom Model Service and its case study “CAIA-Rheumatoid Arthritis Model”

In recent years, we have received many requests about our services, starting from the establishment of patholo…

READ MORE

2024.06.20

PRODUCTS AND SERVICE PUBLICATION

MOA demonstration #2【diponectin】|A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.

We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as M…

READ MORE

2024.06.13

UPDATE

Announcement of webinar: THRβ agonist and preclinical pharmacology study using by STAM™ mice

Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST…

READ MORE

2024.06.04

PUBLICATION

Drug efficacy evaluation study for fibrotic diseases involving multiple organs

If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such a…

READ MORE

2024.05.28

PUBLICATION

Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology

We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on …

READ MORE

2024.04.10

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…

READ MORE

2024.03.22

NEWS RELEASE

【Breaking News!】 First MASH treatment approved by FDA

On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…

READ MORE

2024.03.14

PRODUCTS AND SERVICE

What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?

If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m…

READ MORE

2024.03.12

PRODUCTS AND SERVICE

The [optimal disease model] that maximizes your research outputs.

The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in …

READ MORE

Page 2 of 19First12345Last